26 results
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 24
Leerink Partners LLC
4:55pm
by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department … notice) to:
Leerink Partners LLC
1301 Avenue of the Americas, 12th Floor
New York, New York 10019
Attention: Legal Department
E-mail: legalnotice
6-K
EX-99.1
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health
6-K
EX-1.1
IFRX
InflaRx N.V.
13 Apr 23
Current report (foreign)
4:01pm
of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation as a “specially designated
424B5
IFRX
InflaRx N.V.
13 Apr 23
Prospectus supplement for primary offering
8:48am
have not established an internal audit department. Our board of directors is of the opinion that adequate alternative measures have been taken
424B5
jih 5vtrukg
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.1
03vbkg
8 Sep 22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8:00am
6-K
EX-99.1
rldy9g21x y9s2ne
1 Mar 21
Current report (foreign)
12:00am
424B5
cn1a994htnworyz6c2
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
g0fgk i0l0
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
fitn076y r6j1bhw7
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.1
r5ocnx966yzgq21
14 Sep 20
InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia
7:36am
424B5
9rr4rvjc
20 Jul 20
Prospectus supplement for primary offering
9:21am
6-K
EX-99.1
setmw90
20 Jul 20
from 6-K
9:02am
F-3
7xh08qfi7b ong
8 Jul 20
Shelf registration (foreign)
12:00am
20-F/A
yi52u9u9l4w
29 Mar 19
Annual report (foreign) (amended)
4:23pm